Effects of reference pricing in pharmaceutical markets: A review

PharmacoEconomics

Volumn 29, Issue 1, 2011, Pages 17-33

  Galizzi, Matteo Maria ^a   Ghislandi, Simone ^b   Miraldo, Marisa ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug cost; Formularies; Pricing; Reimbursement.

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTICLE; BELGIUM; CANADA; DRUG COST; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG QUALITY; GERMANY; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUNGARY; ITALY; MEDLINE; NEW ZEALAND; NORWAY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SOUTH AFRICA; SPAIN; SWEDEN;

COMMERCE; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 78650187179     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11537860-000000000-00000     Document Type: Article

References (44)

1. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54 (2): 87-123
2. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effecton pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeco-nomics 2002; 20 (9): 577-91
3. Aaserud M, Dahlgren AT, Kosters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing and purchasing policies. Cochrane Database Syst Rev 2006 Apr 19; (2): CD005979
4. Organisation for Economic Co-operation and Development. Health at a glance 2007: OECD indicators. Paris: OECD, 2007
5. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRIS-MA statement. BMJ 2009; 339: b2535
6. Mestre Ferrandiz J. Reference prices: the Spanish way. Investigaciones Economicas 2003; 27 (1): 125-49
7. Brekke KR, Grasdal AL, Holmas TH. Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation? Eur Econ Rev 2009; 53 (2): 170-85
8. Brekke K, Konigbauer I, Straume O. Reference pricing of pharmaceuticals. J Health Econ 2007; 27 (3): 713-42
9. Zweifel P, Crivelli L. Price regulation of drugs: lessons from Germany. J Regul Econ 1997; 10 (3): 257-73
10. Danzon P, Liu H. Reference pricing and physician drug budgets: the German experience in controlling pharmaceutical expenditures [working paper]. Philadelphia (PA): The Wharton School, 1997
11. Miraldo M. Reference pricing and firms' pricing strategies. J Health Econ 2009; 28 (1): 177-97
12. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand J Econ 2002; 33 (3): 469-87
13. Augurzky B, Gohlmann S, GreX S, et al. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Health Econ 2009; 18 (4): 421-37
14. Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy 2007; 84 (1): 14-29
15. Grootendorst P, Stewart D. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Econ 2007; 15 (7): 735-42
16. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur J Health Econ 2010 Jun; 11 (3): 267-77
17. Mabasa VH, Ma J. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada. J Manag Care Pharm 2007; 12 (5): 371-6
18. Schneeweiss S, Dormuth C, Grootendorst P, et al. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004; 42 (7): 653-60
19. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346 (11): 822-9
20. Hazlet TK, Blough DK. Health services utilization with reference drug pricing of histamine-2 receptor antagonists in British Columbia elderly. Med Care 2002; 40 (8): 640-9
21. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998; 352 (9143): 1830-1
22. Thomas MC, Mann J, Williams S. The impact of reference pricing on clinical lipid control. N Z Med J 1998 Aug 14; 111 (1071): 292-4
23. Simoens S, De Bruyn K, Bogaert M, et al. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeco-nomics 2005; 23 (8): 755-66
24. Schneeweiss S, Soumerai SB, Glynn RJ, et al. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 2002; 166 (6): 737-45
25. Schneeweiss S, Soumerai SB, Maclure M, et al. Clinical and economic consequences of reference pricing for dihydro-pyridine calcium channel blockers. Clin Pharmacol Ther 2003; 74 (4): 388-400
26. Narine L, Senathirajah N, Smith T. Evaluating referencebased pricing: initial findings and prospects. CMAJ 1999; 161 (3): 286-8
27. Marshall JK, Grootendorst PV, O'Brien BJ, et al. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ 2002; 166 (13): 1655-62
28. Grootendorst P, Marshall J, Holbrook A, et al. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv Res 2005; 40: 1297-317
29. Grootendorst P, Dolovich L, O'Brien B, et al. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ 2001; 175 (8): 1011-9
30. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998; 44: 73-85
31. Kalo Z, Muszbek N, Bodrogi J, et al. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 2007; 80 (3): 402-12
32. Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005; 72 (1): 53-73
33. Rothberg AD, Blignault J, Serfontein CB, et al. Experience of a medicines reference-pricing model. S Afr Med J 2004; 94 (3): 183-8
34. Ubeda A, Cardo E, Selles N, et al. Antidepressant utilization in primary care in a Spanish region. Soc Psychiatry Psy-chiatr Epidemiol 2007; 42 (3): 181-8
35. Aronsson T, Bergman M, Rudholm N. The impact of generic drug competition on brand name market shares: evidence from micro data. Rev Ind Organ 2001; 19 (4): 423-33
36. Bergman MA, Rudholm N. The relative importance of actual and potential competition: empirical evidence from the pharmaceuticals market. J Ind Econ 2003; 51 (4): 455-77
37. Andersson K, Petzold M, Sonesson C, et al. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1987-2002. Health Policy 2007; 79 (2-3): 231-43
38. Schneeweiss S, Maclure M, Soumerai SB. Prescription duration after drug copay changes in older people: methodological aspects. J Am Geriatr Soc 2002; 50 (3): 521-5
39. Morgan S, Cunningham C. The effect of evidence-based drug coverage policies onpharmaceutical R&D: a case study from British Columbia. Healthc Policy 2008; 3 (3): 128-53
40. Weiss NS, Heckbert SR. Thrombotic vascular events after change of statin. Lancet 1999; 353 (9155): 844-5
41. Wierzbicki AS, Crook MA, Reynolds TM, et al. Thrombotic vascular events after change of statin. Lancet 1999; 353 (9155): 845
42. Danzon PM, Ketcham JD. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, the Netherlands, and New Zealand. Front Health Policy Res 2004; 7: 1-54
43. Faunce T, Doran E, Henry D, et al. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Global Health 2008; 1 (15): 1-10
44. Faunce TA. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme? Med J Aust 2007 Aug 20; 187 (4): 240-2